Posts by tag
immune checkpoint inhibitors
Ovarian cancer: mechanism conferring resistance to immunotherapy revealed
The presence of flagella, the propellers bacteria use to move, explains why immune checkpoint inhibitors do not work in patients with ovarian cancer. The study, published in Cancer Immunology Research, 11 February, suggests that immune cell recognition of bacterial flagella,…
Study helps solve the puzzle of checkpoint inhibitor myocarditis
The immune reaction that occurs in the hearts of patients taking checkpoint inhibitors who develop immune checkpoint myocarditis may be distinct from the immune responses occurring in the tumours of these patients. The study, published in in Nature, 6 November,…
Anti-oestrogen provides novel strategy to boost checkpoint inhibitors
Adding anti-oestrogen therapy improves response to combined chemotherapy and immune checkpoint inhibition in tumours that do not express oestrogen receptors. The Japanese study, published in British Journal of Cancer, provides a new rationale for introducing therapies blocking oestrogen signalling to…
Stopping immunotherapy after two years does not affect NSCLC survival
No overall survival difference was found between patients with non-small cell lung cancer who stopped immune checkpoint inhibitors at two years and those continuing treatment indefinitely. The study, abstract 9101, presented at the ASCO 2023 Annual Meeting, held June 2–6,…
Personalised RNA vaccine combined with immune checkpoint inhibitor shows efficacy in melanoma
In advanced melanoma, adding a personalised mRNA-based vaccine to the immune checkpoint inhibitor pembrolizumab improved recurrence-free survival compared with pembrolizumab alone. The KEYNOTE-942 study (presentation number CT001), presented at the AACR (American Association for Cancer Research) Annual Meeting 2023, held…
Immunotherapy: three studies point to potential strategies to improve response
Over the past 10 years, immune checkpoint inhibitors (ICIs) have transformed the therapeutic landscape of cancer, becoming standard treatments for metastatic melanoma, renal cell carcinoma, head and neck cancer, and non-small cell lung cancers (NSCLC). “ICIs have revolutionised care in…
No reason to delay cancer immunotherapy following antibiotic use
Exposure to antibiotics prior to anti-PD-1 antibody treatment had no effect on melanoma outcomes. The French study, reported in the Journal of the National Cancer Institute (published March 7, 2022), found using antibiotics in a large cohort of advanced melanoma…